Intravenous Zotatifin in Adults With Mild or Moderate COVID-19
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability, the antiviral activity, and plasma pharmacokinetics
(PK) of zotatifin administered intravenously (IV) to adults with mild or moderate COVID-19.